We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


SCIENION and Greiner Bio-One Enter a Collaboration

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "SCIENION and Greiner Bio-One Enter a Collaboration"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

SCIENION AG and Greiner Bio-One have announced that they have entered into an agreement to co-develop advanced tests and integrated solutions for rapid and multiplexed diagnostics.

The emerging field of rapid diagnostic tests is becoming increasingly important in a variety of applications. For infectious diseases, the time to diagnosis is a critical factor for ensuring successful management.

This collaboration will focus on the development of new tests that will optimize patient care by providing sensitive and accurate test results within only 75 minutes. The collaboration will bring together SCIENION's core competencies in ultra-low volume liquid dispensing, assay miniaturization, and microarray manufacturing with Greiner Bio-One’s innovative Genspeed® testing system.

Dr. Holger Eickhoff, CEO of SCIENION AG, states: "We believe combining our expertise and sciFLEXARRAYER technology with Greiner Bio-One’s Genspeed® platform may enable us to bring personalized healthcare to the next level. We look forward to collaborating with Greiner Bio-One on this exciting development to optimize treatment outcomes for patients."

"We are looking forward to this collaboration to address the significant market need in the detection of human pathogens utilizing our Genspeed® platform", said Dr. Max Sonnleitner, Head of Rapid Testing Technologies/ Business Development at Greiner Bio-One Diagnostics. "Similar to our Genspeed® MRSA testing system, all jointly developed future tests have the potential to become very successful on the market".